A half-hour walk in the morning lowers blood pressure (BP) in overweight and obese men and women predisposed to heart disease, according to a study published in Hypertension Feb. 20.
General Electric CEO Larry Culp told CNBC an initial public offering (IPO) for its healthcare unit, GE Healthcare, is unlikely for 2019 following news that the company plans to sell off its biopharma business.
It costs tens of millions of dollars to approve any new therapy for use in a clinical setting, but a recent analysis published in JAMA Internal Medicine found one class of medication comes at a price more than 100-fold higher than the average: cardiovascular drugs.
The average cardiovascular surgeon drives nearly $3.7 million in net revenue each year for a hospital system, the most among 18 physician specialties included in a survey of hospital chief financial officers. Invasive cardiologists weren’t far behind, ranking No. 2 at almost $3.5 million per year.
More than two years after a major New England Journal of Medicine study declared arthritis drug Celebrex safe for use in heart patients, new research published in JACC: Basic to Translational Science Feb. 22 suggests the drug might actually raise users’ risk for heart valve calcification.
Two U.S. senators launched a bipartisan investigation into rising insulin prices on Feb. 22, sending letters to the drug's top three manufacturers seeking information about why costs have risen so sharply in recent years.
Cardiologists are moderately happy at work compared to other specialists, according to Medscape’s Cardiologist Lifestyle, Happiness & Burnout Report 2019, but they’re still experiencing burnout at record rates.
Patients with coronary artery disease (CAD) enrolled in private insurance plans through Medicare Advantage (MA) are more likely to receive guideline-recommended medications for secondary prevention than those in fee-for-service Medicare, according to a new analysis in JAMA Cardiology. But that wasn't tied to improvements in blood pressure or cholesterol levels.
Researchers used T2 mapping taken from weekly cardiac MRIs to help identify cardiotoxicity at an early stage, according to results of a pig study published Feb. 18 in the Journal of the American College of Cardiology. The findings could help cancer patients at risk of chemo-induced heart failure.
The Orsiro drug-eluting stent. Photo courtesy of Biotronik.
The ultra-thin Orsiro drug-eluting stent (DES) has received FDA approval and is now commercially available in the United States, device manufacturer Biotronik announced Feb. 22.
